AcelRx Pharmaceuticals Inc ACRX disclosed top line results of its ARX-04 final stage study, which met its primary endpoint.
The specialty pharmaceutical company indicated 76 adults were given the treatment with ARX-04 in this trial that witnessed a mean pain intensity difference to baseline (PID) of 2.9 from a baseline of 8.1, or 35 percent, on a 0 – 10 numeric rating scale at 60 minutes. In short, the trial demonstrated reduced pain intensity in ER patients.
Following the news, the stock traded up by $0.39, or 10.46 percent, to $4.12 in the pre-market on Monday.
AccelRx said ARX-04 illustrated a predicted commencement of activity in patients enrolled in SAP302. The company pointed out that patients reported a mean pain intensity fall of 1.1 compared to baseline 15 minutes after the first administration of ARX-04, and a drop of 1.9 following an half-an-hour of the administration of the drug candidate.
The company's co-founder and chief medical officer, Pamela Palmer, said, "In addition to putting combat units in danger, drug-induced cognitive effects can impede diagnosis and treatment in a civilian emergency room. If borne out, ARX-04's onset of pain relief, sublingual dosage form and side effect profile could make it an attractive option for doctors considering opioid analgesic treatment in emergency rooms and field-based settings."
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.